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The need for a consistent therapeutic approach to tendon injury repair is long overdue. Patients with tendon microtears or full
rupturesareeligibleforawiderangeofinvasiveandnoninvasiveinterventions,oftensubjectivelydecidedbythephysician.Surgery
produces the best outcomes, and while studies have been conducted to optimize graft constructs and to track outcomes, the data
from these studies have been inconclusive on the whole. What has been established is a clear understanding of healthy tendon
architecture and the inherent process of healing. With this knowledge, tissue regeneration eﬀorts have achieved immense progress
in scaﬀold design, cell line selection, and, more recently, the appropriate use of cytokines and growth factors. This paper evaluates
the plasticity of bone-marrow-derived stem cells and the elasticity of recently developed biomaterials towards tendon regeneration
eﬀorts. Mesenchymal stem cells (MSCs), hematopoietic progenitor cells, and poly(1,8-octanediol co-citrate) scaﬀolds (POC) are
discussed in the context of established grafting strategies. With POC scaﬀo l d st oc r a d l et h eg r o w t ho fM S C sa n dh e m a t o p o i e t i c
progenitor cells, developing a ﬁbroelastic network guided by cytokines and growth factors may contribute towards consistent graft
constructs, enhanced functionality, and better patient outcomes.
1.Introduction
Sports-related tendon and ligament injuries account for a
signiﬁcant portion of patient presentations, accounting for
many physician hours in primary care, radiology, orthope-
dics, and physical therapy. The function of concentrating
muscle force renders tendons and ligaments susceptible to
overuse syndromes and stress injuries, with pathologies
spanning across three grades [1]. These are overstretching
(grade I, no pain and,no joint instability), partial tears
(grade II, severe pain with joint instability), and complete
tears (grade III, severe pain during injury, followed by
no pain). Complete tears occur most often within the
substance of collagen ﬁbers, particularly during episodes
of fast loading onto tendons and ligaments. In addition,
degeneration and rupture of tendons have been associated
with hypovascularity in certain regions of tissues like the
posterior tibial tendon [2]. Osseous insertion points are
hypervascular, in contrast to other regions prone to stress
and pressure, which are avascular. This explains the tendency
of tendons to rupture within the substance
1.1. Inﬂammatory Cells and Cytokines Drive Tendon Healing.
Upon tissue damage, blood vessels rupture and the exposed
endothelium trigger the coagulation cascade at the site of
injury, producing a hematoma. The hematoma serves to
concentrate ﬁbrin and platelets, with the latter releasing
platelet-derived growth factor(PDGF), transforming growth
factor beta (TGF-β), insulin-like growth factor-1,-2 (IGF-1,
-2), and various cytokines to initiate localized inﬂammation
and establish a chemotatic gradient. In response to the
chemoattractants, neutrophils undergo diapedesis, augment
the levels of TGF-β, and concurrently release additional
factors such as basic ﬁbroblast growth factor (bFGF) and
vascular endothelial growth factor (VEGF). Meanwhile,
histamine and bradykinin from platelets and neutrophils
promote the formation of prostaglandins (PGE1 and PGE2),2 Stem Cells International
which collectively present as symptoms of pain and tender-
ness [3]. After the acute inﬂammatory phase, the level of
concentrated growth factors allows the transition into the
reparative stage, occurring through either an extrinsic or
intrinsic pathway.
In the extrinsic tendon repair scheme, the tear repairs
itself through granulation tissue formation [4]. A scar devel-
ops after initial macrophage phagocytosis of debris, followed
by activation of dormant ﬁbroblasts, ﬁbroblast migration
and collagen deposition at day three after injury. Lactate
from tissue hypoxia is the impetus for collagen deposition
[5].Macrophagesrespondtohighlactatelevelsandstimulate
ﬁbroblasts to lay down extracellular matrix components,
either directly or through TGF-β. By day seven, angiogenesis
driven by VEGF is noticeable in order to support ﬁbroblast
activity [6]. Unfortunately, collagen ﬁbers deposited under
the extrinsic repair pathway lack organization [7]d u et o
abnormal cross-linking and a predominance of type III
collagen. The high level of retained glycosaminoglycans
results in a weaker, ﬁbrotic tendon that is less able to glide
smoothly within its sheath [8].
In contrast, the intrinsic repair mechanism mimics
embryonic tendon formation [9]. In this system, ﬁbrob-
lasts migrate to the site of defect and are responsible for
synthesizing collagen ﬁbrils of a single variety. Procollagen
from the rough endoplasmic reticulum is cleaved into
tropocollagen, and, instead of linking to form collagen
ﬁbers directly, they are added to collagen ﬁbril segments
ﬁrst. These ﬁbril segments are larger than tropocollagen
molecules,whichuponincorporationintodamagedcollagen
at the ruptured ends, maintain the original and intended
orientation of subunits, as seen in organized embryonic
ﬁbrillogenesis [10–13]. The ﬁnal stages of repair start 6–
8 weeks after injury and last for months thereafter. Type
III collagen is replaced by type I collagen, and a reduction
in cellularity and water content allows the healing ten-
don to approach the morphology of normal functioning
tissue.
Nutrition to the tendon is critically important in both
normal physiology and healing after pathology [14]. Typi-
cally, intrasynovial tendon are supported by intrinsic cells
found in the single-cell-layered synovial membrane. This
membrane exists over the tendon (endotenon), on the
parietal surface of the tendon sheath (epitenon), and within
the adventitia (paratenon). Extrasynovial tendons receive
nourishment from growth factors and cytokines available
in the paratenon and systemic vasculature. These factors
include IGF-1, PDGF, bFGF, each especially vital in the early
and immediate stages of healing. They initiate and guide
ﬁbroblast activation, proliferation, and migration. TGF-β
and VEGF display their importance in the remodeling phase,
prompting angiogenesis [3].
2.CurrentTherapeuticStrategies
The approach to treatment in acute soft tissue trauma
relies heavily on the patient’s history, signs, and symptoms
including the grade of injury, and their goals of usage after
therapy. Initially, clinical evaluation determines the grade of
injury and the level of instability to the joint. Radiologic
techniques of ultrasound and magnetic resonance imaging
assist the diagnosis, after which the patient is considered for
conservative or surgical treatment. For all injuries, initial
management is aimed at controlling edema, increasing sta-
bilityanddecreasingpainandinﬂammation.Thesegoalscan
be achieved by protection, rest, ice, compression, elevation
and support.
2.1. Non Surgical Approach. F o rs m a l lt e a r so ro v e r u s e
injuries, physicians opt for conservative therapy to
strengthen and stretch the tendon. After all, older patients
with co morbidities and arthritis are less eligible for surgery,
particularly if the therapeutic intent is achieving stability
over high-intensity, sport-related joint use [15]. Some
injuries are even considered irreparable [16]. Non surgical
rehabilitation involves immobilization and strengthening
of the muscles around the joint. This approach relies
on the intrinsic and extrinsic mechanisms of repair as
discussed above. While movement, stretching or heat is not
recommended during the inﬂammatory phase (weeks 0–3),
a gradual progression towards controlled weight-bearing
exercise and plyometrics is allowed for the reparative
and remodeling stages (weeks 3–12). At a cellular level,
stretching and strengthening encourage collagen synthesis
[17]. Without appropriate physical therapy, collagen ﬁbrils
are not arranged linearly and yield a weak scar prone to
further injury. Early mobilization of the joint followed by
late passive or active motility prevents complications like
adhesions to the synovium [18].
2.2. Surgical Approach. For young patients hoping to achieve
pre injury conditions of use, surgical interventions can
reconstitute function up to 98%. Surgery, however, is not
without diﬃculties. Suture techniques are numerous, and
selecting an appropriate graft is a further challenge. For
anterior cruciate ligament injuries, gracilis hamstring auto-
grafts are commonly harvested, but great attention must
be given to attain appropriate tension and ﬁxation of the
graft in surgery. A ﬂaccid graft, or one over-tightened,
would compromise stability and range of motion. Still,
surgery remains an optimal choice. In Achilles tendon
ruptures, surgical treatment was associated with a lower
risk of re rupture compared to other interventions [19].
In addition, complications such as infection, nerve damage,
adhesions, and disturbed skin sensibility must be con-
sidered with open surgery [20–23]. Recent insights have
revealed that percutaneous approaches to tendon repair
tend to minimize infection and improve patient satisfac-
tion despite the inability of the surgeon to visualize the
defect [24]. While the cosmetic diﬀerence between the
open and percutaneous method is noteworthy, there is still
contention as to whether the percutaneous approach has
an eﬀect on the rates of tendon re rupture, the residual
gap between blunted ends, or the level of nerve injury
[25–27].Stem Cells International 3
Recently, therapies using autologous platelet-rich plasma
(PRP) injections are being explored. PRP mimics the high
concentration of platelets in the hematoma surrounding
the site of injury [28]. A bolus of PRP includes platelets
(up to six times more concentrated than in blood), TGF-
β, PDGF, VEGF, IGF-1, ﬁbrin, ﬁbronectin, vitronectin,
thrombospondin, osteonectin, and osteocalcin [29]. While
this appears mechanistically ideal, randomized controlled
trials have shown little to no improvement on disease
progress [30, 31]. The appropriate dosage of PRP for soft
tissue injuries remains unknown, and the eﬀects rely heavily
on anatomical site and grade of injury as well [29].
For certain patient populations, especially those with
complete ruptures, surgery is the standard of care for tendon
and ligament injuries [32]. Even with advances in surgery,
there still remains an inherent need to establish physiological
function with a high degree of reproducible outcomes for
patients. While the lack of clear post operative rehabilitation
protocols may contribute to this [33], ﬁndings from a meta-
analysis by Mohtadi et al. [34] elaborate on the issue.
In comparing the outcomes of anterior cruciate ligament
repairs with autologous hamstring or patellar tendons, no
diﬀerences were found in function or rates of rerupture.
However, patellar grafts were shown to produce a more
stable knee, at the expense of anterior knee discomfort and
decreased range of extension. Patients with a hamstring
graft had weaker knees and a decreased range of ﬂexion
range and strength. Evidently, neither graft is optimal.
Looking forward, the open surgical strategy invites the
use of biomaterials and autologous stem cells to enhance
nativerepairmechanisms,areconstructionstrategythatmay
address this uncertainty in patient outcomes.
3. Mesenchymal Stem Cells asa Candidatefor
Tendon andLigament Repair
Tenocytes, or elongated ﬁbroblast cells resident to the
tendon, are responsible for the generation of collagen ﬁbers
in ﬁbrillogenesis but remain fairly dormant in normal
usage conditions. Upon injury, they are activated by the
inﬂammatory response for collagen deposition. To conduct
this function, tenocytes are assisted by tendon-derived stem
cells (TDSCs). Studies have shown that TDSCs induce
tenocyte diﬀerentiation upon mechanical stimulation [35].
Fromtheregenerativestandpoint,ligamentsandtendons
can be considered structurally similar. Type I collagen pre-
dominates in both ﬁbroelastic structures, with the remaining
substanceconsistingofﬁbroblasts,groundsubstance,elastin,
and water [36]. Ligaments have a slightly reduced collagen
ﬁbril percentage, but a higher elastin and proteoglycan
component compared to tendons. Moreover, within the
category of tendons, no signiﬁcant diﬀerences have been
documented in construct or elasticity between males and
females [37]. Nonetheless, their major diﬀerence is in
function, not composition. By healing the collagen ﬁbers
similarly in tendons and ligaments, construction of grafts
b e c o m e sm o r ee ﬃcient to reinstate sustained tensile loads
after injury.
The regenerative capacity of mesenchymal stem cells
is now well established in a multitude of ﬁelds, including
orthopedics [38–42]. Although rare in the bone marrow,
occurring at a rate of one in 100,000 nucleated cells [43],
MSCs possess a high, though not indeﬁnite, proliferation
capacity that compensates for their rarity. They are capable
of dividing 24–40 times to expand the cell population to
well above one million cells [44]. MSCs express cell surface
markers CD29, CD44, CD105 and CD166 and are negative
for hematopoietic markers such as CD14, CD34, and CD40.
MSCsarealsonegativeforleukocytecommonantigenCD45,
suggesting that these stem cells cannot stimulate allogeneic
lymphocyte proliferation and will thus avoid immune
rejection [45]. Their distinction from hematopoietic cells
of the bone marrow allows ease of isolation through ﬂow
cytometry, making MSCs readily available for use [46].
One great advantage of MSCs, as described by Pittenger
et al. [47], is that they do not diﬀerentiate spontaneously
during in vitro culture. This permits a controlled micro
environment, such as the target tissue itself, to dictate the
diﬀerentiation of MSCs after implantation. From a regen-
eration perspective, MSCs display an immunomodulatory
eﬀect [48] that includes the secretion of cytokines to initiate
tissue regeneration [49]. At present, multipotent MSCs have
been diﬀerentiated into neural [50], cardiac, osteogenic,
and adipogenic lineages. The plasticity inherent in MSCs
makes this cell a prime candidate for soft tissue regeneration,
particularly since they support orthopedic healing with
minimal complications [51].
3.1. MSCs Appear Similar to TDSCs. In a characterization
study, undiﬀerentiated TDSCs were compared to bone-
marrow-derived mesenchymal stem cells (BM-MSCs) as
also important in regeneration. TDSCs were found to
have a higher clonogenicity and proliferation rate, and
expression proﬁles revealed a higher level of tenomodulin,
scleraxis, COL1A1, alkaline phosphatase, COL2A1, and
biglycan mRNA expression compared to BM-MSCs [52].
While TDSCs appear more suited for regeneration of soft
tissue, these soft tissue-speciﬁc mRNAs were not absent
from MSCs, indicating their capacity to act like TDSCs. A
summary comparing TDSCs and MSCs presented in Table 1.
Given the capacity of MSCs to be inﬂuenced by their
microenvironment,itisexpectedthatMSCsinthecontextof
thetendonsheathwouldupregulaterelevantproteincontent
to that found in TDSCs. Direct and compelling evidence
has already shown the ability of MSCs to diﬀerentiate into
tenocytes [53,54].Inaddition,MSCsaremoreeasilyisolated
and banked from bone marrow compared to TDSCs, which
are harvested from fragile peritendinous connective tissue
[55]. From a therapeutic perspective, isolating connective
tissuefromthesiteofinjuryrequirestwoinvasiveprocedures
at the same site, whereas bone marrow aspiration will not
aggravate the healing process at the tendon rupture location.
In an eﬀort to reconstitute ﬂexor tendon tissue, Kryger
et al. [55] demonstrated the similarities between diﬀeren-
tiated epitenon tenocytes and BM-MSCs. Morphologically,
BM-MSCsandtenocyteswerebothspindleshaped,andboth4 Stem Cells International
Table 1: Immunohistochemical comparison of MSCs and TDSCs.
Cellular marker Bone-marrow-derived mesenchymal stem cells [47, 114–116] Tendon-derived stem cells [117, 118]
CD18 −−
CD31 −−
CD34 −−
CD40 −−
CD44 + +
CD45 −−
CD90 + +
CD90.2 − +
CD105 + +
CD106 + −
CD117 −−
CD144 + −
CD146 + +
Sca-1 − +
Oct-4 + +
SSEA-4 + +
Stro-1 − +
Nucleostemin − +
Flk-1 + −
Tenomodulin + ++
Scleraxis + ++
Cartilage oligomeric protein (Comp) + ++
Tenascin + ++
Sox-9 + +
Runx2 + +
COL1 + ++
COL2 −−
α-smooth muscle actin ++ +
Fibronectin + +
stained strongly for collagen 1 and 3 [56]. Like BM-MSCs,
tenocytes showed no senescence across multiple passage
rounds, illustrating the long-term capacity of both cell
types to support regeneration in grafts. If growth was not
sustained over the course of healing, applications of MSCs
would be stunted from arrested growth in the more complex
synovial environment. When seeded upon acellular tendon
grafts, both cell types retained their collagen architecture
in vivo with an inﬂammatory response equal to that of
controls. These characteristics support the use of BM-MSCs
for tendon regeneration, particularly when part of seeded
scaﬀolds [57–59]. Like TDSCs, MSCs have been induced
to diﬀerentiate to tenocytes through the Wnt signaling
pathway and cyclic mechanical stimulation that mimics
normal processes [60]. Interestingly, platelet-rich plasma
(PRP) was found to stimulate both MSCs and TDSCs. PRP
enhanced MSC proliferation towards soft tissue lineages and
induced TDSC diﬀerentiation into tenocytes [61, 62]. True
validation that MSCs are a viable candidate would illustrate
a tenocyte-like mRNA and protein proﬁle, as well as active,
yet controlled, collagen deposition.
4. Elastomeric Scaffolds and
Biomimetic Materials
It is now well appreciated that seeded grafts vastly improve
outcomes over unseeded grafts [57–59]. When Langer and
Hubbell began using biomimetic self-assembling scaﬀolds,
they determined that a successful graft must display several
properties: (a) the scaﬀold should support cell adherence,
(b) local growth factors should accumulate and be released
when appropriate, and (c) the scaﬀold should be resistant to
matrix proteases [63–66]. The success of many scaﬀolds has
lent credence to these core concepts and should thus be an
integral aspect of scaﬀold design.
The inception of soft tissue regeneration eﬀorts began
with using small intestinal submucosa (SIS) as substituteStem Cells International 5
for graft material harvested from the patient. SIS is a
xenogenic membrane harvested from porcine jejunum [67].
Mechanical removal of the muscularis and mucosa yields
a thin, translucent submucosa. Decellularization produces
a dense, native collagen matrix that is readily usable for
a multitude of tissue engineering ﬁelds. Since the recent
Food and Drug Administration approval of this material,
SIS has been used for rotator cuﬀ reconstructions [68].
The collagen matrix in SIS is immediately ready for graft
purposes, and the extracellular proteins (elastin, laminins,
ﬁbronectins,andproteoglycans)conferanadditionallayerof
stability to the product. By removing cellular contents with
peracetic acid, cytokines and growth factors of the digestive
organ are removed to allow better acceptance in other sites
like synovium.This strategy,however,violates currenttrends
of using autologous sources of tissue. Harvesting SIS can
elicit an immunologic reaction and diminish its applicability
for patients since an ampliﬁed inﬂammatory response can
lead to tissue damage and poor wound healing. SIS has been
shown to undergo contracture in vivo, and the high batch-
to-batch variability limits the potential in therapeutics.
Recently, collagen matrices cultured with MSCs have
appeared on the horizon for tendon repair [69–71]. The
promising technique of isoelectric focusing aligns collagen
ﬁbers to the parameters of the target tissue, adjusting to the
density, alignment, and strength of dense connective tissue.
These electrochemically aligned collagen (ELAC) matrices
support a higher proliferation rate of MSCs compared to
randomly oriented collagen. The mere orientation of ELAC
upregulates scleraxis and tenomodulin in MSCs, supporting
the shift towards tenogenic diﬀerentiation of MSCs when
presented with an aligned and dense collagen substrate.
ELAC scaﬀolds, however, only fulﬁll the mechanical pre-
requisites of scaﬀold design. While collagen orientation and
MSC adherence is important, ELAC does not support the
incorporation of growth factors and cytokines needed in
healing.
4.1.Poly(1,8 octanediol-co-citrate)ScaﬀoldsforTendonRegen-
eration. Currently, the versatility of synthetic polymers
shows great promise in tissue engineering. A novel material,
ﬁrst established in therapeutics by Ameer et al. [72], and
subsequently by Sharma et al. [73], is presented here for
consideration in tendon regeneration. Poly(1,8 octanediol-
co-citrate) scaﬀold (POC) is a highly reproducible elas-
tomeric material [72, 73] capable of being used as a synthetic
scaﬀold to support cell growth. By means of comparison, a
similar material called poly(lactide-co-glycolic acid) (PLGA)
has been previously utilized to deliver stem cells for tendon
regeneration eﬀorts [74]. PLGA is capable of achieving an
elastic modulus comparable to tendons (750 MPa), with a
degradation pattern lasting seven weeks in vitro.
The selection of POC over other compounds such as
PLGA or poly-glycolic acid (PGA), however, stems beyond
their composition. Both PLGA and POC are porous enough
to support cell growth, and both degrade to similar nontoxic
byproducts. Yet, POC is thinner allowing greater oxygen
a n dﬂ u i de x c h a n g e( h e n c eag r e a t e rd e l i v e r yo fn u t r i e n t s
to developing tissue) across opposing faces, which beneﬁt
cell proliferation in the long run. POC scaﬀolds can also
be customized to a higher degree than PLGA, allowing the
dynamics of elasticity to better reﬂect native ligament and
tendon dynamics. Despite exhibiting equal support of robust
cell growth, the three-dimensional PLGA structure does not
suture well onto living tissue.
POC scaﬀolds provide adhesion substrates for anchor-
ing cells and delivering growth factors through controlled
release upon scaﬀold degradation [75]. POC scaﬀolds
are biodegradable and resorbable—they degrade by non-
enzymatic hydrolysis into CO2 and H2O. These polymers
form highly adaptable and labile scaﬀolds due to their
ester bonding scheme and are rapidly reproducible as
well. While POC scaﬀolds lack any biological property, the
polymerization conditions can be optimized so that POC
scaﬀolds mimic the tensile strength and Young’s modulus
of collagen-based elastic tissue. Brieﬂy, when equimolar
amounts of citric acid and 1,8 octanediol are combined,
melted, and cooled to make a prepolymer, polymerization
dynamics can be thereafter adjusted based on temperature
and time parameters [76]. High temperatures with short
polymerization times yield denser thin ﬁlms, while low
temperatures and long polymerization times produce lower
cross-linked ﬁlms. These properties make POC a superior
scaﬀold to non degradable constructs for two reasons. First,
a second surgery to remove the device is not necessary,
and non degradable scaﬀolds tend to not reproduce the
mechanical behavior of the target tissue. Tables 2(a) and 2(b)
exhibit the scaﬀolds presently available for therapeutic or
experimental use [69, 73, 77–86].
The physical properties of POC can be exquisitely tai-
lored for a variety of tissue morphologies and functions. For
example,athinlayerofPOCwouldhavenodiﬃcultyserving
as a graft for both round (Achilles) and ﬂat (rotator cuﬀ)
tendons. Moreover, POC scaﬀolds would graft equally well
onto unsheathed and sheathed tendons, without hindering
smooth gliding. For tendons that angle around bony promi-
nences, POC scaﬀolds would be ﬂexible enough to maintain
this conformation and remain intact throughout motion.
The Young’s modulus, measured according to Hooke’s
law under stress/strain conditions, is readily available for
most tendon and ligamentous structures (Table 3). Hence,
crafting POC scaﬀolds according to these elasticity and
stiﬀnessvaluesallowforaconsistentconstructionforspeciﬁc
anatomical targets. Additional parameters, such as Poisson’s
ratio, hysteresis, and creep, would further characterize the
target tissue and allow for an even better matched scaﬀold
design.
While the majority of tendon and ligament ruptures
occur in the body of tendon, a proportion do occur at
the ﬁbrocartilage interface as well. In this region, colla-
gen ﬁbers blend into the bony attachment as perforating
ﬁbers (Sharpey ﬁbers) that become continuous with the
periosteum. During slowly increasing loading rates on the
ligament, the insertion point of ﬁbers becomes the weakest
point. The importance of this junction has recently become a
targetfortherapeuticsaswell,sinceweaknessatthisinterface
can jeopardize even the best eﬀorts of reconstruction.6 Stem Cells International
Table 2: (a) Dermal scaﬀolds for tendon and ligament augmentation. (b) Synthetic scaﬀolds for tendon and ligament augmentation.
(a)
Scaﬀold Composition Status Support for growth factor release?
Matrix xenografts
Restore Porcine SIS FDA approved Yes (TGF-β,V E G F ,F G F - 2 )
CuﬀPatch Porcine SIS FDA approved Yes (EGF, TGF-β,F G F )
TissueMend Bovine dermal extracellular matrix FDA approved No
Zimmer collagen repair patch Porcine acellular dermal matrix FDA approved No
Permacol Porcine acellular dermal matrix FDA approved No
Conexa Porcine acellular dermal matrix Experimental No
Matrix allografts
GraftJacket Human acellular dermal matrix FDA approved Yes
(b)
Scaﬀold Status Support for growth factor release?
Non degradable synthetic polymers
Polyethylene terephthalate (Stryker-Dacron) FDA approved No
Polypropylene (Kennedy Ligament Augmentation Device) FDA approved Yes
Poly(tetraﬂuoro ethylene) (GoreTex) FDA approved Yes
Biodegradable Synthetic Polymers
Polylactic acid FDA approved Yes
Polyglycolic acid FDA approved Yes
Poly(lactide-co-glycolic acid) FDA approved Yes
Polydioxanone FDA approved No
Polycaprolactone FDA approved Yes
Hydrothane/PET FDA approved
x-Repair Device (poly-L-lactide) FDA approved Yes
Hyaluronan-based non woven mesh (HYAFF11) Experimental Yes
Electrochemically aligned collagen matrices (ELAC) Experimental No
Poly(1,8-octanediol-co-citrate) Experimental Yes
Nanoﬁber matrices
Peptide Amphiphiles Experimental Yes
Table 3: Young’s Modulus of Human Tendons and Ligaments. Young’s Modulus = stress/strain = (F/A)/(ΔL/Lo).
Tendon or ligament Young’s modulus (MPa) Reference
Gracilis 612.8 Butler et al. [119]
Semitendinous 362.2 Butler et al. [119]
Patellar 1090 Hansen et al. [120]
Lateral collateral ligament 350–400 Butler et al. [121]
Posterior cruciate ligament 300–400 Butler et al. [121]
Anterior cruciate ligament 300–350 Butler et al. [121]
Tibialis Anterior 1200 Maganaris and Paul [122]
Infraspinatus 527 Halder et al. [123]
T e r e sm i n o r 1 4 H a l d e re ta l .[ 123]
Gastrocnemius tendon 1160 Maganaris et al. [123, 124]
A detailed discussion by Mikos et al. emphasizes that
regeneration of the interface is a “prerequisite for achieving
biological ﬁxation of soft tissue grafts” [87]. In one study,
MSCs were shown to accelerate the remodeling of the tendo
osseous interface when implanted into bone tunnels [88],
implying that MSCs have a potential in this region as well.
Instead of attaching tendinous grafts to bone via screws,
the optimal approach is reconstruction using the collabora-
tionofsyntheticmaterialswithMSCs.Paradoxically,thevery
complexity of the ﬁbrocartilage interface makes it a perfect
candidate for POC utilization. Mimicking the strategy of Lu
and colleagues [89], a scaﬀold with three distinct regionsStem Cells International 7
Table 4: Summary of growth factors necessary in tendon regeneration.
Growth factor Size (kDa) Function
TGF-β 25 Promotes angiogenesis and collagen production
EGF 6.4 Mitogenic to ﬁbroblasts and promotes collagenase activity to
remodel the extracellular matrix
PDGF-β 12.3 Mitogenic to ﬁbroblasts, chemoattractant to macrophages, and
assists angiogenesis
bFGF 22–24 Released from extracellular matrix to promote angiogenesis and
granulation
VEGF 38.2 Vasculogenesis and angiogenesis during tissue hypoxia
Hepatocyte growth factor (HGF) α chain: 69
β chain: 32–34
Expressed in wound ﬁbroblasts to regulate growth, motility, and
morphogenesis
BMP-12,13,14 30–38 Promotes tendon-derived stem cell diﬀerentiation into tenocytes
Early growth response factor-1 (EGR-1) 75 Transcription factor that upregulates collagen and accelerates
wound closure
would allow formation of collagenous tendon along one
edge, osseous material along the other, and a middle zone
representing the transition from tendon to bone. Given
the capacity of MSCs to diﬀerentiate into osteogenic and
tenogenic lineages, a single cell population seeded onto
the scaﬀold could regenerate the complex ﬁbrocartilage
interface. Additionally, POC scaﬀolds could be crafted
according the target tendon interface, relying on Wolﬀ’s Law
to govern the dynamics and load of the tendon aimed for
reconstruction.
5. GrowthFactorsand
Cytokines for Angiogenesis
While mature tendons are poorly vascularized and sustained
by synovial ﬂuid [90], developing tendons are highly vascu-
lar. The rich capillary network associated with tenogenesis
arises mainly from the muscle-tendon junction, the osteo-
tendinous junction, or from the surrounding connective tis-
sue [91]. As described, tendons may revert to an embryonic
state of intrinsic repair in order to lay down collagen after
injury. From a vascular standpoint, it is not unexpected
then that acutely injured tendons sprout capillary buds at
the site of laceration [90]. Indeed, clinicians are careful to
preserve the richly vascular connective tissue around the
injury in order to surround the graft. Avoiding necrosis and
supplementing the graft so that synovial ﬂuid is not the only
source of nutrition is key to graft survival [90, 92].
Vasculogenesis at the site of injury is dependent on
VEGF [93]. Through tyrosine kinase receptors, VEGF guides
hemangioblasts to diﬀerentiate into endothelial progenitors,
which form new vessels to supply the site of injury. When
angiogenic responses are induced by wounding, endothelial
progenitorsarerapidlymobilized.AidedbyFGF-1,2,TGF-β,
PDGF, and TNFα [94, 95] from tenocytes and surrounding
connective tissue, these cytokines and growth factors sup-
port tendon grafts and promote tissue remodeling. Results
from embryologic studies reveal that TGF-β increases the
transcription factor scleraxis [96]. Scleraxis is key to tendon
maturation, and even in adenoviral-mediated transduction
of MSCs with scleraxis gene, the tissue demonstrated
improved stiﬀness, increased stress-to-failure levels, and
a greater deposition of ﬁbrocartilage [60]. A systematic
review of pertinent growth factors adds cartilage-derived
morphogeneticprotein(CDMP),IGF,VEGF,IL-10,andFGF
to the repertoire of factors necessary in tendon regeneration
[97]. These factors are summarized in Table 4 [98–107].
Enhancing the reparative eﬀects of a vascular network
around the site of injury can be achieved through direct,
localized delivery of proangiogenic factors. Eﬀorts to trans-
fect these factors into cells, or deliver factors through
liposomal-mediated gene transfer, have been improvements
to direct infusion of recombinant growth factors [108].
However, this approach may not be appropriate for the
tendon microenvironment, since delivery schemes would
not reach avascular regions of the tendon. Moreover, naked
DNA transfection relies on cellular transcription factors to
produce the angiogenic factors, placing great responsibility
upon already damaged tissue to support itself.
The inherent properties of POC oﬀer an alternative
means of growth factor delivery. During the polymerization
of POC, small kDa-sized growth factors may be locked
within the scaﬀold and released upon surface erosion. In
a study by Sharma et al. [75], elastomeric POC scaﬀolds
were modiﬁed with heparan sulfate and loaded with VEGF,
FGF2, and IGF-1 prior to rat implantation. These con-
structs released the pro-angiogenic growth factors through
a systematic and controlled degradation and produced an
increased vascular growth in vivo as compared to controls.
Heparan sulfate, a highly sulfated glycosaminoglycan, serves
to protect bound growth factors and extend their half-life.
Such a construct would also permit the delivery of factors to
modulate degradative enzymes in the healing tissue [16].
Alternatively, POC may be seeded with primitive stem
or progenitor cells alongside MSCs. Sourced from the same
origin as MSCs, this prevents unnecessary intrusion into
patients, as a single bone marrow aspiration can yield ample
cells of each population. Discovery and use of CD34+
hematopoietic stem cells (HSCs), expressing von Willebrand8 Stem Cells International
Factor (vWF), vascular endothelial-cadherin (VE-cadherin),
and Flk-1, proved to increase neovascularization and reduce
ﬁbrosis when injected to the site of injury [109, 110]. These
markers, in addition to CD133, CD34 and AC133 [111],
allowforeaseofisolationthroughﬂowcytometry.Giventhat
endothelial progenitors are compatible with synthetic sup-
port matrices [112], blood vessel elongation and branching
will beneﬁt from the porosity of POC scaﬀolds as the cell-
scaﬀoldconstructmatures.Meticulousstudieswouldhaveto
be conducted to track the termination of neovascularization,
since mature tendons are avascular. It is presumed that an
overgrowthofvesselswouldhinderthestabilityandfunction
of the graft. At present, the use of stem cells in orthopedic
scaﬀolds is limited to animal studies only [16].
6. PresentBarriersandFutureDirections
The combinatorial eﬀect of MSCs, POC scaﬀolds, and
growth factorscreatesa strong approach totreating common
tendon injuries. While Gulotta et al. [35] refutes the thera-
peutic eﬀects of MSCs in tendon healing, our approach may
suggest otherwise. Findings that state MSCs did not improve
structure, composition, or strength of the tendon [35]c a nb e
attributed to the lack of growth factor use in the construct.
Additionally,thedeliveryofcellsthroughaﬁbrinmatrixmay
not be a suitable substrate for MSC diﬀerentiation under in
vivo conditions.
Initiating a tendon regeneration process requires the
identiﬁcation and isolation of appropriate cell types that
are able to proliferate and sustain growth over the healing
processwhilemaintainingphysiologicalintegrityofthegraft.
The function potential of MSCs and CD34+ HSCs is directly
dependent on proper synthetic scaﬀold design. In conso-
nancewithPOCscaﬀolds,weexploitthevastpotentialMSCs
to lay down collagen and hematopoietic precursors to weave
vessels through the tapestry of the scaﬀold. Reinforcements
after surgery with therapy and NSAIDs have been shown to
increase insoluble and total collagen, translating to increases
in tensile strength and restoration [113].
Since POC can be customized to various densities, the
application of such a versatile scaﬀold expands beyond
orthopedics. Here, formation of dense regular connective
tissue was discussed, but POC may farewell in regener-
ating dense irregular and loose areolar connective tissue
as well. For example, POC scaﬀolds could contribute to
three conditions that utilize tissue engineering: (a) dermal-
epidermal reconstitution for burn victims with MSCs to
supply ﬁbroblasts and adipose tissue, (b) urinary bladder
wall regeneration in neurogenic conditions with MSCs
supplying contractile smooth muscle cells, and (c) cartilage
formationforosteoarthritisandmeniscaltears.Ineverycase,
the functional trio of MSCs, POC, and growth factors may
one day supplement current surgical tactics.
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